Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimer’s Disease

Frontiers in Aging Neuroscience - Switzerland
doi 10.3389/fnagi.2019.00149
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors

Journal of Biomedicine and Biotechnology
2011English

Can Arginase Inhibitors Be the Answer to Therapeutic Challenges in Alzheimer’s Disease?

Neurotherapeutics
NeurologyPharmacology
2018English

Innovative Strategies for Selective Inhibition of Histone Deacetylases

Cell Chemical Biology
Molecular MedicineMolecular BiologyPharmacologyBiochemistryClinical BiochemistryDrug Discovery
2016English

Exploring Glia to Better Understand Alzheimer’s Disease

Animal Cells and Systems
Animal ScienceZoologyGeneticsMolecular BiologyBiochemistry
2018English

Adenosine Mimetics as Inhibitors of NAD+-Dependent Histone Deacetylases, From Kinase to Sirtuin Inhibition

English

Exploiting Microglial and Peripheral Immune Cell Crosstalk to Treat Alzheimer’s Disease

Journal of Neuroinflammation
Molecular NeuroscienceNeurologyImmunologyCellularNeuroscience
2019English

Advances in Developing Novel Therapeutic Strategies for Alzheimer’s Disease

Molecular Neurodegeneration
Molecular NeuroscienceNeurologyMolecular BiologyCellular
2018English

Are NSAIDs Useful to Treat Alzheimer’s Disease or Mild Cognitive Impairment?

Frontiers in Aging Neuroscience
AgingCognitive Neuroscience
2010English

Harnessing Nature’s Insight: Design of Aspartyl Protease Inhibitors From Treatment of Drug-Resistant HIV to Alzheimer’s Disease†

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy